ID | 61307 |
FullText URL | |
Author |
Sugiura, Hiroyuki
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Nishimori, Hisakazu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
Nishii, Kazuya
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Toji, Tomohiro
Department of Pathology, Okayama University Hospital
Fujii, Keiko
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Fujii, Nobuharu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Matsuoka, Ken-ichi
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
Nakata, Koh
Department of Bioscience Medical Research Center, Niigata University Medical & Dental Hospital
Kiura, Katsuyuki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
Maeda, Yoshinobu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
|
Abstract | Pulmonary alveolar proteinosis (PAP) is an uncommon lung disorder characterized by the excessive accumulation of surfactant-derived lipoproteins in the pulmonary alveoli and terminal bronchiole. Secondary PAP associated with primary myelofibrosis (PMF) is extremely rare, and to our knowledge, no autopsy case has been reported. We herein report an autopsy case of secondary PAP occurring in a patient with PMF who was treated with the Janus kinase 1/2 inhibitor ruxolitinib. We confirmed a diagnosis of PAP with complications based on the pathological findings at the autopsy. Notably, this case might suggest an association between ruxolitinib treatment and PAP occurrence.
|
Keywords | pulmonary alveolar proteinosis
primary myelofibrosis
autopsy
ruxolitinib
|
Published Date | 2020-08-15
|
Publication Title |
Internal Medicine
|
Volume | volume59
|
Issue | issue16
|
Start Page | 2023
|
End Page | 2028
|
ISSN | 0918-2918
|
NCID | AA10827774
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © 2020 by The Japanese Society of Internal Medicine
|
File Version | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.4082-19
|
License | https://creativecommons.org/licenses/by-nc-nd/4.0/
|